Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FBRX 
Forte Biosciences Inc (FBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: FBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $52.25
1 Year Target Price $52.25
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.46% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 153.30M USD | Price to earnings Ratio - | 1Y Target Price 52.25 |
Price to earnings Ratio - | 1Y Target Price 52.25 | ||
Volume (30-day avg) 4 | Beta 2.69 | 52 Weeks Range 4.11 - 28.68 | Updated Date 09/17/2025 |
52 Weeks Range 4.11 - 28.68 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.79% | Return on Equity (TTM) -73.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36585163 | Price to Sales(TTM) - |
Enterprise Value 36585163 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.87 | Shares Outstanding 12432900 | Shares Floating 10222044 |
Shares Outstanding 12432900 | Shares Floating 10222044 | ||
Percent Insiders 4.96 | Percent Institutions 85.47 |
Upturn AI SWOT
Forte Biosciences Inc
Company Overview
History and Background
Forte Biosciences, Inc. was founded in 2016. It focused on developing and commercializing a live biotherapeutic for inflammatory skin diseases. In 2022, Forte Biosciences divested its assets.
Core Business Areas
- Drug Development (Historical): Forte Biosciences focused on developing and commercializing FB-401, a live biotherapeutic for treating inflammatory skin diseases like atopic dermatitis. However, this project and focus has been abandoned.
Leadership and Structure
Leadership details are less relevant now after the changes to the company's strategy. Historically, the company had a CEO and a board of directors.
Top Products and Market Share
Key Offerings
- FB-401 (Historical): FB-401 was Forte Biosciences' primary product candidate. Clinical trial results were mixed, and development was discontinued. Competitors in the atopic dermatitis market include Sanofi (SNY) and Regeneron (REGN) with Dupixent.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies developing novel therapies for various diseases. The atopic dermatitis market is characterized by established players and emerging therapies.
Positioning
Historically, Forte Biosciences aimed to establish itself in the atopic dermatitis market. Their competitive advantage was based on the novel mechanism of action of their biotherapeutic. However, with FB-401 gone, its competitive advantage has diminished considerably.
Total Addressable Market (TAM)
The atopic dermatitis market is estimated to be several billion dollars. Forte Biosciences' prior potential market share depended on the success of FB-401.
Upturn SWOT Analysis
Strengths
- Novel approach to atopic dermatitis treatment (Historical)
- Strong scientific team (Historical)
Weaknesses
- Single product focus (Historical)
- Clinical trial risk (Historical)
- Limited financial resources
Opportunities
- Potential for partnerships (Historical)
- Expansion into other indications (Historical)
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- SNY
- REGN
Competitive Landscape
Forte Biosciences faces intense competition from established pharmaceutical companies with greater resources and approved therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by the development of FB-401.
Future Projections: Future growth is highly uncertain given the strategic shift.
Recent Initiatives: Recent initiatives involved asset divestiture and strategic reevaluation.
Summary
Forte Biosciences underwent a significant strategic shift after mixed clinical trial results for FB-401. The company divested its assets, resulting in a highly uncertain future. Investors should carefully assess the company's new direction and financial position. The company needs to find new direction and regain investor confidence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports (Historical)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Forte Biosciences Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2017-04-13 | CEO, President & Chairman Dr. Paul A. Wagner Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.fortebiorx.com |
Full time employees 17 | Website https://www.fortebiorx.com | ||
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.